

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

SNU-423

RRID:CVCL_0366

Type: Cell Line

Proper Citation

RRID:CVCL_0366

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0366

Proper Citation: RRID:CVCL_0366

Description: Cell line SNU-423 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:7543080](#), [PMID:8824565](#), [PMID:19956504](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:25485619](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Korean., Part of: Seoul National University (SNU) cell line collection., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-423

Synonyms: SNU423, NCI-SNU-423

Cross References: BTO:BTO_0003187, CLO:CLO_0009099, EFO:EFO_0002348, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2238, BioGRID_ORCS_Cell_line:813, BioSample:SAMN03471849, BioSample:SAMN03473132, BioSample:SAMN10987943, cancercellines:CVCL_0366,

Cell_Model_Passport:SIDM01199, ChEMBL-Cells:CHEMBL3308367, ChEMBL-Targets:CHEMBL1075584, CLS:305874, Cosmic:871513, Cosmic:909737, Cosmic:1177681, Cosmic:1995641, Cosmic:2023869, Cosmic:2162532, Cosmic:2321037, Cosmic-CLP:909737, DepMap:ACH-000493, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909737, GEO:GSM565923, GEO:GSM887626, GEO:GSM888711, GEO:GSM936781, GEO:GSM1670470, GEO:GSM2551588, IARC_TP53:6308, IGRhCellID:SNU423, KCLB:00423, LiGeA:CCLE_063, LIMORE:SNU423, LINCS_LDP:LCL-1935, PharmacoDB:SNU423_1461_2019, PRIDE:PXD030304, Progenetix:CVCL_0366, PubChem_Cell_line:CVCL_0366, Wikidata:Q54955197

ID: CVCL_0366

Record Creation Time: 20220427T221552+0000

Record Last Update: 20260904T015715+0000

Ratings and Alerts

No rating or validation information has been found for SNU-423.

No alerts have been found for SNU-423.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. Cancer research communications, 6(1), 178.

Jang SH, et al. (2026) Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. Molecular oncology.

Wang LT, et al. (2026) ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer. Experimental hematology & oncology, 15(1).

Xiao C, et al. (2025) Pharmacological targeting of large tumor suppressor kinases (LATS) 1 and 2 augments tissue repair and regeneration. British journal of pharmacology.

Mesropian A, et al. (2025) E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(23), 5037.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. *Cancer research*, 85(4), 660.

Missiaen R, et al. (2022) GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. *Cell metabolism*, 34(8), 1151.

Wang H, et al. (2021) Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. *Cell reports*, 34(8), 108765.

Wang YP, et al. (2021) Malic enzyme 2 connects the Krebs cycle intermediate fumarate to mitochondrial biogenesis. *Cell metabolism*, 33(5), 1027.

Cabrera-Cano A, et al. (2021) Hypoxia as a modulator of cytochromes P450: Overexpression of the cytochromes CYP2S1 and CYP24A1 in human liver cancer cells in hypoxia. *Cell biochemistry and function*, 39(4), 478.

Golkowski M, et al. (2020) Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. *Cell systems*, 11(2), 196.

Tarumoto Y, et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. *Molecular cell*, 69(6), 1017.

Dai N, et al. (2017) IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1. *eLife*, 6.